Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Egyptian Atomic Energy Authority (EAEA) aromatase compound 10: sourced facts only. name: "Also, compound 10 was the most potent aromatase inhibitor with the lowest IC50 (0.06 μM) compared to letrozole (IC50 0.05 μM)." [PMID:40239405]; target: "Also, compound 10 was the most potent aromatase inhibitor with the lowest IC50 (0.06 μM) compared to letrozole (IC50 0.05 μM)." [PMID:40239405]; developer: "Department of Drug Radiation Research, National Center for Radiation Research and Technology (NCRRT), Egyptian Atomic Energy Authority (EAEA), Cairo 11787, Egypt." [PMID:40239405]; stage: "Compound 10 exhibited a promising cytotoxic activity (IC50 1.83 μM) that nearly equal to the reference drug (doxorubicin, IC50 1.94 μM) on MCF-7 cells." [PMID:40239405]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Egyptian Atomic Energy Authority (EAEA) aromatase compound 10.